HYL — Hyloris Pharmaceuticals SA Balance Sheet
0.000.00%
- €176.40m
- €154.07m
- €8.46m
Annual balance sheet for Hyloris Pharmaceuticals SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 64.4 | 50.5 | 43.9 | 30.9 | 24.1 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.253 | 2.32 | 4.13 | 3.81 | 5.37 |
Total Other Current Assets | |||||
Total Current Assets | 66.6 | 54 | 49.8 | 35.3 | 29.7 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.176 | 0.295 | 1.06 | 2.15 | 1.99 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 69.2 | 63.4 | 60.7 | 47.7 | 41.3 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.13 | 15 | 5.77 | 6.76 | 7.16 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 10.1 | 15.4 | 6.82 | 8.61 | 9.19 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 59.1 | 48.1 | 53.9 | 39.1 | 32.1 |
Total Liabilities & Shareholders' Equity | 69.2 | 63.4 | 60.7 | 47.7 | 41.3 |
Total Common Shares Outstanding |